Paeds · allergy-and-immunology
Immunoglobulin replacement and antimicrobial prophylaxis
Also known as Immunoglobulin replacement therapy · IVIG and SCIG · Antibody replacement · Prophylactic antibiotics in immunodeficiency · Infection prophylaxis in primary immunodeficiency
A fellowship approach to immunoglobulin replacement and antimicrobial prophylaxis in children with antibody deficiency: confirm the defect and the functional need before committing to lifelong immunoglobulin, choose the route (intravenous versus subcutaneous) around the family's life and the trough goal, dose to clinical outcome rather than a number alone, layer antimicrobial prophylaxis where immunoglobulin is insufficient or not indicated, and protect the lung and the transition to adult care.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Starting immunoglobulin replacement on a single low immunoglobulin value without a proven functional defect or documented infection susceptibility
- Live vaccines given to a child with a possible combined immunodeficiency before the immune status is clarified
- Persistent breakthrough infection despite an adequate immunoglobulin trough — escalate investigation and add or change antimicrobial prophylaxis rather than simply raising the dose
- IgA-deficient patient with anti-IgA antibodies exposed to IgA-containing blood products — risk of anaphylaxis
- Severe headache, aseptic meningitis, haemolysis, thrombosis, or renal impairment after intravenous immunoglobulin — a recognised adverse-effect cluster
- Specific antibody deficiency treated with immunoglobulin before a trial of antibiotic prophylaxis has been considered
- Faltering growth or new structural lung disease in a child established on immunoglobulin — reassess regimen and adherence
Life stages
Care settings
Clinical exam formats
Board mappings
- General and Community Paediatrics
- Infectious Diseases, Immunology and Allergy
- Therapeutics and Prescribing
- Allergy and immunology - recognise, investigate and manage primary immunodeficiency and recurrent infection
- Pharmacology and therapeutics - safe prescribing of high-risk medicines
- Renewed curriculum for first-year trainees from 2027 - Learning goal 6: Clinical management - essential general paediatrics
- Immunology and Allergy 10-12
- Clinical Applications
- Medical Sciences
- Long Cases
- Short Cases
- 9. Infection, Immunology and Allergy
- 4. Professional skills and knowledge: Patient management
- 7. Patient safety, including safe prescribing
- Foundation of Practice (FOP)
- Theory and Science (TAS)
- Applied Knowledge in Practice (AKP)
- Clinical
- History
- Communication
- Video
- General Pediatrics Content Outline - D17 Allergy and Immunology (3%)
- General Pediatrics Content Outline - D15 Infectious Diseases (8%)
- General Pediatrics Content Outline - Universal Task 4: Management and Treatment
- Patient Care 4: Clinical Reasoning
- Patient Care 5: Patient Management
- Medical Knowledge 3: Allergy and Immunology
- Systems-Based Practice 1: Patient Safety
- Medical Expert
- Pediatrics: Foundations EPA #8 - Communicating assessment findings and management plans to patients and/or families
- Pediatrics: Allergy and Clinical Immunology (0-5%)
A six-year-old boy with X-linked agammaglobulinaemia has been on intravenous immunoglobulin since infancy, dosed every four weeks in a hospital two hours from his home. He has had three breakthrough pneumonias this year despite a trough IgG that looks acceptable on paper. Two questions now decide his future. First, is trough wrong target — should his regimen be driven by his infection rate rather than the number? Second, would a switch to home subcutaneous immunoglobulin give him the steady troughs and the life back that his current regimen cannot? Holding those two questions together — dose to outcome, fit the route to the family — is the whole skill of this topic. [2] [7]
Document the defect before treating (quantified immunoglobulins plus a functional vaccine response). · Outcome drives the dose, not the trough number alone — count infections and watch the lung. · Subcutaneous Ig for steady troughs, fewer systemic reactions, and home self-infusion. · Escalate to antimicrobial prophylaxis when breakthrough infection persists despite an adequate trough. · United protection — vaccinate household contacts, never give live vaccines if a combined defect is possible. · Protect the lung and plan the transition to adult immunology. [2] [8]
Overview & Definition
Immunoglobulin replacement is the regular administration of pooled human immunoglobulin G to restore the antibody that a child with a significant antibody deficiency cannot make for themselves. Antimicrobial prophylaxis is the scheduled use of an antibiotic, antiviral, or antifungal agent to prevent infection in a child whose immune system cannot reliably clear it. The two are used together, in sequence, or alone, depending on the defect, the infection burden, and the child's response. [1]
The unifying principle is that treatment is matched to a proven functional need, never to a number alone. Immunoglobulin replacement carries real costs and real risks — infusion reactions, headache, the rare but serious thrombotic, haemolytic, and renal events, line-related infection, and the dependence of a child on a blood product for life. Starting it without a confirmed defect trades a reversible or self-limiting problem for a permanent one. The same logic applies in reverse: a child with a real defect who is under-dosed to a textbook trough will keep infecting their lung. [2] [3]
The indications, dosing, and route choice rest on a defined evidence base. The American Academy of Allergy, Asthma and Immunology Primary Immunodeficiency Committee reviews, first in 2006 and updated in 2017, set out who benefits from immunoglobulin and on what evidence; the 2015 practice parameter frames the diagnostic and management standard; and the 2022 International Union of Immunological Societies classification names the conditions that qualify. A fellowship answer is built on these sources, not on a single regimen memorised from a formulary. [1] [4]
References10ShowHide
- [1]Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol, 2015.PMID 26371839
- [2]Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol, 2017.PMID 28041678
- [3]Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol, 2006.PMID 16580469
- [4]Bousfiha A, Moundir A, Tangye SG, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol, 2022.PMID 36198931
- [5]Suez D, Stein M, Gupta S, et al. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20% in Patients with Primary Immunodeficiency Diseases in North America. J Clin Immunol, 2016.PMID 27582171
- [6]Joud Hajjar, Nguyen AL, Constantine G, et al. Prophylactic Antibiotics Versus Immunoglobulin Replacement in Specific Antibody Deficiency. J Clin Immunol, 2020.PMID 31758281
- [7]Pulvirenti F, Cinetto F, Pecoraro A, et al. Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study. J Clin Immunol, 2019.PMID 30644015
- [8]Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol, 2012.PMID 22730009
- [9]Duff C, Ballow M Nuts and Bolts of Subcutaneous Therapy. Immunol Allergy Clin North Am, 2020.PMID 32654697
- [10]Gathmann B, Grimbacher B, Beauté J, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol, 2009.PMID 19630863